The global personalized medicine market size was estimated at USD 567.10 billion in 2024 and is projected to reach USD 1,196.18 billion by 2033, growing at a CAGR of 8.80% from 2025 to 2033. The increasing demand for targeted therapies and precision diagnostics is a major factor driving the growth of the personalized medicine market. As healthcare systems move toward individualized treatment models, the emphasis on tailoring therapies to meet specific patient needs is becoming increasingly critical in improving clinical outcomes and overall healthcare efficiency.
Advancements in genomic technologies, biomarker discovery, and data-driven treatment strategies are enabling healthcare providers to design therapies that align closely with each patient’s unique genetic and molecular profile. This personalized approach not only enhances the effectiveness of treatments but also minimizes the risk of adverse effects, reduces trial-and-error prescribing, and ensures more efficient utilization of healthcare resources. With the global rise in chronic and complex diseases such as cancer, diabetes, and cardiovascular disorders, the adoption of personalized medicine continues to accelerate, fostering innovation and investment in diagnostics, therapeutics, and health data integration platforms.
Personalized diagnostics play a vital role in this transformation by providing more accurate disease identification, enabling earlier interventions, and supporting improved patient management. For instance, in 2024, Illumina’s FDA-approved TruSight Oncology Comprehensive test demonstrated the power of personalized diagnostics by analyzing over 500 genes to guide targeted cancer treatments effectively. Such breakthroughs highlight how precision diagnostics are reshaping clinical decision-making and treatment planning.
Moreover, increasing awareness among patients regarding genetic predispositions and the benefits of DNA-based testing is further driving the adoption of personalized healthcare solutions. As individuals become more proactive about understanding their genetic risks and health profiles, the demand for customized prevention and treatment approaches continues to rise. This growing shift toward proactive, patient-specific, and technology-driven care models is expanding the market’s potential across various medical specialties, reinforcing personalized medicine as a cornerstone of the future healthcare landscape.
Key Market Trends & Insights:
• North America dominated the global personalized medicine market, accounting for the largest share of 40.17% in 2024. The region’s leadership is primarily attributed to its advanced healthcare infrastructure, strong presence of key market players, and high adoption of precision medicine practices. The widespread integration of genomics, digital health technologies, and data analytics into clinical workflows has further strengthened the region’s position. In addition, supportive government initiatives and substantial investments in research and development aimed at enhancing targeted therapies and genetic testing have played a crucial role in driving market growth.
• Within the region, the U.S. personalized medicine industry is projected to witness substantial growth throughout the forecast period. This expansion is driven by the increasing prevalence of chronic diseases, growing awareness about genetic-based healthcare, and the rapid incorporation of artificial intelligence and big data analytics in treatment planning. Moreover, strong collaborations between research institutions, biotechnology companies, and healthcare providers are accelerating innovation and the development of new personalized therapies. The country’s favorable regulatory environment and emphasis on patient-centered care continue to support the widespread adoption of personalized medicine solutions.
• Based on product segmentation, the personalized nutrition and wellness segment held the highest market share of 32.0% in 2024. This dominance can be attributed to the growing consumer focus on preventive healthcare, lifestyle management, and diet personalization through genetic testing and digital health platforms. Increasing awareness of the connection between nutrition, genetics, and overall well-being is encouraging individuals to adopt tailored diet and fitness programs designed to meet their specific metabolic and health requirements.
• By end use, the hospitals segment accounted for the highest market share in 2024. Hospitals remain the primary setting for implementing personalized medicine due to their access to advanced diagnostic tools, specialized medical expertise, and integrated care networks. The rising adoption of genomic testing, targeted drug therapies, and precision diagnostics in hospital environments has significantly contributed to this segment’s dominance. Additionally, hospitals play a vital role in facilitating multidisciplinary collaboration among clinicians, researchers, and genetic counselors, enabling the effective delivery of customized treatment plans and improving patient outcomes.
Order a free sample PDF of the Personalized Medicine Market Intelligence Study, published by Grand View Research.
Market Size & Forecast:
• 2024 Market Size: USD 567.10 Billion
• 2033 Projected Market Size: USD 1,196.18 Billion
• CAGR (2025-2033): 8.80%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market
Key Companies & Market Share Insights:
Illumina, Inc. and QIAGEN are among the leading players in the personalized medicine market, driving growth through their advanced sequencing technologies and molecular diagnostic solutions designed to support individualized treatment approaches. Their innovations enable healthcare providers to analyze genetic variations with greater accuracy, facilitating more precise diagnosis and targeted therapy selection for a wide range of diseases.
GE Healthcare and IBM continue to hold strong positions in the market by integrating artificial intelligence (AI) and data analytics into healthcare systems. Their advanced health data platforms and AI-driven clinical decision support tools help physicians interpret complex patient data, optimize treatment decisions, and improve overall care efficiency. These technologies play a crucial role in connecting genomics, imaging, and real-time patient monitoring to create comprehensive, data-informed treatment pathways.
Exact Sciences Corporation and Danaher Corporation (through its subsidiary Cepheid, Inc.) are expanding their market presence by offering high-precision diagnostic solutions, particularly in oncology and infectious diseases. Their innovative molecular and point-of-care diagnostic products are enhancing early disease detection and enabling more effective personalized treatment strategies.
Abbott and Dako A/S are leveraging their extensive diagnostic product portfolios and advanced laboratory automation systems to improve the accuracy, speed, and scalability of personalized diagnostics. Their solutions are instrumental in supporting precision testing, thereby contributing to better clinical outcomes and operational efficiency within healthcare settings.
Meanwhile, Biogen and Genentech, Inc. are advancing targeted therapeutic development through intensive research focused on neurodegenerative disorders and oncology. Their efforts in drug discovery and biomarker identification are shaping the future of individualized medicine, ensuring that therapies are specifically tailored to patient-specific biological profiles.
Overall, the personalized medicine market remains highly competitive, fueled by growing demand for customized healthcare solutions, expanding applications in predictive medicine, and continuous innovation across diagnostics, therapeutics, and digital health platforms. Companies are increasingly focusing on integrating technology, data, and biology to deliver more precise, efficient, and patient-centric care.
Key Players
• GE Healthcare
• Illumina, Inc.
• ASURAGEN, INC.
• Abbott
• Dako A/S
• Exact Sciences Corporation
• Danaher Corporation (Cepheid, Inc.)
• Decode Genetics, Inc.
• QIAGEN
• Exagen Inc.
• Precision Biologics
• Celera Diagnostics LLC.
• Biogen
• Genelex
• International Business Machines Corporation (IBM)
• Genentech, Inc.
Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.
Conclusion:
The personalized medicine market is poised for substantial growth, driven by rising demand for targeted therapies and precision diagnostics, advancements in genomics and biomarker identification, and the shift toward individualized healthcare. As chronic and complex diseases continue to grow globally, healthcare systems are increasingly adopting tailored treatment strategies, spurring innovation across diagnostics, therapeutics, and digital health platforms.
